HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alberto-Culver sales up 22.2% to $396.1 mil. in second quarter 1996.

This article was originally published in The Rose Sheet

Executive Summary

ALBERTO-CULVER USA EARNINGS UP OVER 60% ON 20% SALES GAIN IN SECOND QUARTER of FY 1996 (ended March 31), the Melrose Park, Ill.-based company said April 25. The firm pointed to the acquisition of St. Ives, which includes the Swiss Formula hair and skin care brands, as "playing an important part in supplementing growth of the company's core brands and businesses."

You may also be interested in...



Alberto sales up 11.6% to $347.6 mil. in first FY 1996 quarter.

ALBERTO SALES ADVANCE 11.6% TO $347.6 MIL. IN FIRST QUARTER of FY 1996 (ended Dec. 31) as gains from the company's International and Sally Beauty businesses offset declines in the USA group, the Melrose Park, IL-based firm reported Jan. 25. Net earnings for the quarter grew 15% to $12.9 mil

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel